Klus Pharma to Attend the 15th Annual World ADC in San Diego

Klus Pharma will attend the 15th Annual World ADC in San Diego being held from November 4-7th, 2024. The World ADC San Diego is the largest global ADC-focused conference held annually and provides a prominent platform for ADC industry representatives to meet, share, and discuss the latest updates in ADC-related research and clinical development, as well as exploring potential collaboration opportunities within the ADC field. With more than 1,200 attendees expected to attend, including from leading ADC companies, we are looking forward to hearing all the promising progress made in the field this year. We are also excited to announce that our parent company, Kelun-Biotech, has been shortlisted across three categories at the 11th Annual World ADC Awards this year, and the full list can be found at the following link:
https://worldadc-awards.com/about/2024-shortlist/

Klus Pharma is the US subsidiary of Kelun-Biotech, an innovative China-based drug developer that has become a well-recognized and major player in the ADC field through its recent collaborations with Merck (known as MSD outside the United States and Canada) for several ADC candidates. Since the inception of Kelun-Biotech in 2016, the Company has steadily built up its own proprietary ADC platform, OptiDC, which is based on irreversible conjugation chemistry, highly stable and adjustable linkers, and a novel topoisomerase-I inhibitor payload with bystander effect. Leveraging this platform alongside our talented team of scientists and clinicians has allowed the creation of more than ten promising ADC molecules, four of which are being advanced in ongoing clinical trials: sacituzumab tirumotecan (TROP2 ADC), A166 (HER2 ADC), SKB315 (Claudin 18.2 ADC), and SKB410 (Nectin-4 ADC).

In addition, several "next-generation" ADC candidates are undergoing preclinical studies, which includes testing of various linker-payload strategies and antibody formats. We would also be interested in exploring the potential of developing new ADC candidates with companies that have novel antibodies, linker-payload strategies, and/or other ADC-enhancing technologies.